FDA issues safety alert for Arrow International guidewire components over coating detachment risks
The U.S. Food and Drug Administration issued an Early Alert on November 10, 2026, about a medical device removal by Arrow International, a subsidiary of Teleflex Incorporated. On November 5, 2026, the company sent a letter asking customers to stop using, distribute, and quarantine specific products containing hydrophilic-coated spring wire guide components. These devices include marked guidewires and pressure-injectable catheters used to place medical lines, administer medication, and draw blood. Tests confirmed that the coating on these wires can swell unevenly when exposed to saline. This defect may cause the coating to clump and detach inside a patient's body. Detached pieces can release particles into the bloodstream, creating emboli that may lead to severe complications such as strokes, tissue damage, or death. As of November 5, 2026, Arrow International reported no serious injuries or deaths connected to the issue. Customers holding these products should immediately isolate them and contact the company for returns.
What was announced
The Center for Devices and Radiological Health at the FDA issued an Early Alert regarding a potentially high-risk issue with medical devices made by Arrow International, a Teleflex Incorporated subsidiary. On November 5, 2026, Arrow International sent a letter to affected customers recommending that they remove specific products containing hydrophilic-coated spring wire guide components from service.
The affected devices include Arrow Marked Guidewires and various Pressure Injectable Arrowg+ard Blue Advance PICC and JACC catheter kits. Arrow coated guidewires assist with catheter placement in blood vessels, while the catheter sets deliver fluids, administer medicines, and take blood samples. Teleflex confirmed that the coating on the wire components may swell inconsistently when hydrated with saline. This swelling leads to coating clumping and potential detachment.
What it means
Healthcare facilities and distributors must immediately stop using and distributing the listed products. Affected items should be quarantined right away and returned to Teleflex and Arrow International. Customers must also forward the recall notice to any recipients who received impacted devices.
If the hydrophilic coating detaches during a procedure, fragments can enter the bloodstream. This creates a risk of hydrophilic polymer emboli. These blockages can trigger adverse health events, including inflammation, blood clots, tissue injury, reduced blood flow, stroke, additional medical interventions, or death. Arrow International reported no serious injuries or deaths related to this issue as of November 5, 2026. U.S. customers can contact Arrow International by email at Recalls@teleflex.com or by phone at 1-866-396-2111.
What the announcement does not tell us
The alert does not state the total number of individual devices affected by the removal. It does not clarify how long the affected devices were sold or distributed prior to the recall notice.
The announcement does not explain how the coating defect was first discovered or whether specific lot numbers are affected. Furthermore, the FDA does not state when it will complete its full review of the issue, though it committed to posting updates as new information arrives.
How this was written
This analysis was written with AI from the official announcement below, using only facts that announcement states. The quoted wording is FDA MedWatch Safety Alerts’s own. Always check the original before acting on anything here.
Spring Wire Guides containing hydrophilic coating may detach and release particles into the bloodstream, risking embolism.
Opens www.fda.gov
More from FDA MedWatch Safety Alerts
- Game Changer Products LLC Issues Voluntary Nationwide Recall of 10 Day Forecast Capsules Due to the Presence of Undeclared Sildenafil and Acetaminophen12 November 2026
- Early Alert: Intersurgical Inc. Removes 22mm Smoothbore breathing tubes and systems10 November 2026
- Heart Pump Controller Recall: Abiomed Removes Automated Impella Controllers (AIC)9 November 2026
- Eugia US LLC (f/k/a Auro Medics Pharma LLC) Issues Voluntary Nationwide Recall of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial) Due to Presence of Particulate Matter9 November 2026
- MedWatch Alert: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication9 November 2026
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.